Article
Differentiating MYCN-amplified RB1 wild-type retinoblastoma from biallelic RB1 mutant retinoblastoma using MR-based radiomics: a retrospective multicenter case-control study.
Scientific reports - 23 Oct 2024
de Bloeme Christiaan M, Jansen Robin W, Cardoen Liesbeth, Göricke Sophia, van Elst Sabien, Jessen Jaime Lyn, Ramasubramanian Aparna, Skalet Alison H, Miller Audra K, Maeder Philippe, Uner Ogul E, Hubbard G Baker, Grossniklaus Hans, Boldt H Culver, Nichols Kim E, Brennan Rachel C, Sen Saugata, Koob Mériam, Sirin Selma, Brisse Hervé J, Galluzzi Paolo, Dommering Charlotte J, Cysouw Matthijs, Boellaard Ronald, Dorsman Josephine C, Moll Annette C, de Jong Marcus C, de Graaf Pim
Abstract excerpt
MYCN-amplified RB1 wild-type (MYCNampRB1+/+) retinoblastoma is a rare and aggressive subtype, often resistant to standard therapies. Identifying unique MRI features is crucial for diagnosing this subtype, as biopsy is not recommended. This study aimed to differentiate MYCNampRB1+/+ from the most prevalent RB1-/- retinoblastoma using pretreatment MRI and radiomics. Ninety-eight unilateral retinoblastoma patients...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.